A New Beginning

Oncology & Biotech News, December 2015, Volume 9, Issue 12

OncLive Chairman,

Mike Hennessy

It is with great pleasure that I announce that starting in 2016, Oncology & Biotech News (OBTN) will become part of its sister publication, OncologyLive, the flagship publication of OncLive, the nation’s leading digital and print resource for oncology professionals.

In January, OncologyLive will start to publish twice monthly, with expanded coverage of emerging therapeutic strategies and research developments. Along this line, the new bimonthly version of OncologyLive will include an OBTN section that will allow the publication to provide even more timely and dynamic reports about the latest cutting-edge oncology data and FDA actions, including new drug approvals. The OBTN section will also infuse the publication with more extensive coverage of major oncology meetings held in the United States and internationally.

Becoming part of OncologyLive will also double the reach of OBTN’s content, as OncologyLive is mailed to more than 22,000 oncology specialists, including medical oncologists, hematologists, radiation oncologists, urologists, gynecologic oncologists and head and neck surgeons.

In addition to the OBTN section, the unique and robust mix of information that will be offered in the new bimonthly OncologyLive includes in-depth articles that feature the insights of the worldrenowned oncologists who participate in Physicians’ Education Resource meetings; the OncPathways series, which examines the newest findings about cell-signaling networks; the Precision Medicine in Oncology section, which focuses on a wide range of emerging diagnostics; and articles written by faculty members from prominent cancer centers through the OncLive Strategic Alliance Partnership program, which encompasses nearly 60 oncology care institutions. It has been a privilege reporting to you from the frontlines of oncology innovation in the pages of OBTN, and we look forward to continuing this great tradition as part of OncologyLive in 2016.